Sofgen Pharma S.A.
PRCWF
Other OTC0.00
USD
- -
- -
ISIN
LU2376491259
CUSIP
237649125
Return %
Stock
S&P500
1Y
- -
18.99
3Y
- -
64.75
5Y
- -
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Melissa Angelini
- Full Time Employees
- 5,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 Rue de Bitbourg Luxembourg City Luxembourg 1273
- IPO Date
- Apr 3, 2023
- Website
- sofgenpharma.com
- Similar Companies
- Business
- Sofgen Pharma S.A. engages in the research, development, manufacturing, and distribution of pharmaceutical and nutraceutical solutions, with a focus on high-end softgel technologies, complex oral modalities, and hormonal/high-potency compounds. The company operates as an integrated CDMO/CMO offering end-to-end services including formulation development, process development, technology transfer, clinical and pre-clinical support, manufacturing, packaging, and quality control, as well as specialized nutraceuticals and hospital supplies. Headquartered in Luxembourg, Sofgen maintains a multinational footprint with direct operations in multiple countries and serves customers across North America, Latin America, Europe, and beyond. Founded in 2010, it emphasizes advanced delivery technologies, orphan/fast-track development pathways, and differentiated manufacturing capabilities to support prescription drugs, generics, OTC products, and niche nutraceuticals. The organization is structured around core units and capabilities that enable end-to-end product lifecycle management from concept to commercial supply, including regulatory support, analytical services, and supply chain functions. In addition to its Sofgen Softgel platform, the company collaborates with regional partners and affiliates to expand market access, provide contract development and manufacturing services, and deliver customized dosage forms for complex therapeutic areas such as oncology and endocrinology. The firm pursues strategic collaborations and portfolio expansion to enhance its global reach, product offerings, and manufacturing scale, positioning itself as a key partner for pharmaceutical innovators seeking differentiated softgel and oral formulation solutions. Sofgen operates under the broader corporate umbrella of its parent group, with subsidiaries and regional entities supporting regional market penetration and local regulatory compliance. The company emphasizes commitment to quality, regulatory excellence, and customer-focused service, aiming to deliver reliable development and manufacturing solutions that meet international standards and support patient needs.
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership